Behçet’s disease, a chronic inflammatory disorder, presents unique challenges during pregnancy, affecting both maternal and neonatal outcomes. The limited and conflicting literature on Behçet’s disease and pregnancy notes varying disease activity among patients and even within the same individual across pregnancies. While hormonal influences may induce an anti-inflammatory pathway, resulting in disease stabilization or remission during pregnancy, the risk of obstetric complications remains increased, especially in active patients with Behçet’s disease. This chapter focuses on treatment algorithms for patients with Behçet’s disease during pregnancy and lactation. In this section, in accordance with current guidelines, the discussion will cover, sequentially, drugs proven to be compatible with the treatment of Behçet’s disease during pregnancy and lactation, drug groups that are teratogenic and contraindicated for use during pregnancy, biological agents, and paternal drug use. We believe that the treatment strategies discussed in this chapter will be valuable for clinicians dealing with pregnant and breastfeeding patients with Behçet’s disease.